Medifast (MED) Tops Q4 EPS by 24c, Misses on Revenue; Offers Q1 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Medifast (MED) PT Lowered to $16.50 at DA Davidson
February 19, 2025 1:01 PM ESTDA Davidson analyst Linda Bolton Weiser lowered the price target on Medifast (NYSE: MED) to $16.50 (from $17.00) while maintaining a Neutral rating.
The analyst comments "NEUTRAL-rated MED reported a 4Q24 beat. In December, it launched the Ascend line for people who were... More
